MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
Our results suggest that MGBS, calculated solely from the MHC genotype, has clinical potential as a non-invasive and tumor-independent biomarker to guide anti-cancer immunotherapy in melanoma.
Authors
- Jimmy Van den Eynden (ORCID: https://orcid.org/0000-0003-0002-5614)
- A. Claeys (ORCID: https://orcid.org/0000-0001-6990-1569)
Institutions
- Ghent University (BE)
- Cancer Research Institute Ghent (BE)
Publication Details
- Journal
- Communications Medicine
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1038/s43856-024-00612-w
- Citations
- 3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Broad Institute
- Universiteit Gent
- Kom op tegen Kanker
- Stand Up To Cancer
- Bijzonder Onderzoeksfonds UGent
- National Human Genome Research Institute